4D Molecular Therapeutics, Inc.

Healthcare

NASDAQ:FDMT · NASDAQ Global Select

Market Cap $461.60M Beta 2.76 P/E (TTM) -3.7

$8.83 -0.06%

-$0.01 today

52W Low $3.68High $12.34

Vol 0.56M · Avg 0.76M

EPS (TTM)-$2.36

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+101.14%

Period High

$12.27

Period Low

$3.71

Latest

$8.83

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

$1.44B

Lexicon Pharmaceuticals, Inc.

NASDAQ:LXRX

$852.86M

Omeros Corporation

NASDAQ:OMER

$632.20M

Prothena Corporation plc

NASDAQ:PRTA

$431.91M

REGENXBIO Inc.

NASDAQ:RGNX

$344.31M

Neumora Therapeutics, Inc. Common Stock

NASDAQ:NMRA

$329.81M

Bicycle Therapeutics plc

NASDAQ:BCYC

$281.05M

Compass Therapeutics, Inc.

NASDAQ:CMPX

$280.72M

ADC Therapeutics S.A.

NYSE:ADCT

$133.55M

Gossamer Bio, Inc.

GOSS

$38.00M

What is the latest FDMT filing?

The latest filing shown is 4 dated Jun 2, 2026.

How many recent filings does FDMT have?

Intrinsic Alpha currently shows 20 recent filings for FDMT.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.